Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
Int J Lab Hematol ; 37(5): 686-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25996654

ABSTRACT

IgM multiple myeloma (MM) is a rare subtype of myeloma that shares clinical and pathological features with Waldenström's macroglobulinaemia. These are two separate entities that differ both in therapy and prognosis. We report a 57-year-old male, who presented with anaemia, hypercalcaemia, acute renal failure and several vertebral fractures that clinically suggested a multiple myeloma. Further investigations revealed a serum monoclonal component of IgM lambda type and a bone marrow infiltrated by small, lymphoplasmocytic cells. IgM MM was finally diagnosed by means of both inmunophenotypic and immunohistochemistry techniques, stressing the importance of inmunophenotypic evaluation when clinical and morphological features are discordant. Fluorescence in situ hybridization (FISH) studies disclosed a particular combination of deletion 13q14, t(11;14) and monoallelic deletion C-MAF without t(14;16). The clinical evolution after a Bortezomib-containing polychemotherapy and autologous stem cell transplantation (ASCT) conditioned with busulphan and melphalan is also presented. This very uncommon case highlights the impact of immunophenotyping on the differential diagnosis between IgM MM and WM, to choose the best treatment and establish an appropriate outcome.


Subject(s)
Gene Deletion , Immunoglobulin M/blood , Multiple Myeloma/blood , Multiple Myeloma/genetics , Proto-Oncogene Proteins c-maf/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone Marrow/pathology , Diagnosis, Differential , Humans , Immunophenotyping , Male , Middle Aged , Multiple Myeloma/diagnosis , Multiple Myeloma/drug therapy , Treatment Outcome , Waldenstrom Macroglobulinemia
SELECTION OF CITATIONS
SEARCH DETAIL
...